Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7300318 | 0.85 | MEN1 (0.59) | MEN1KMT2ASMN1; SMN2HTTNPC1 | |
| SCHEMBL28058459 | 0.81 | MEN1 (0.40) | MEN1KMT2ASMN1; SMN2HTTNPC1 | |
| SCHEMBL23087216 | 0.80 | MEN1 (0.66) | MEN1KMT2AHTTNPC1RAB9A | |
| SCHEMBL20540314 | 0.79 | MEN1 (0.39) | MEN1KMT2ASMN1; SMN2HTTNPC1 | |
| SCHEMBL15880434 | 0.78 | MEN1 (0.38) | MEN1KMT2ASMN1; SMN2HTTNPC1 | |
| SCHEMBL20539629 | 0.78 | MEN1 (0.38) | MEN1KMT2ASMN1; SMN2HTTNPC1 | |
| SCHEMBL12988824 | 0.76 | LPAR1 (0.53) | SMN1; SMN2NPC1RAB9A | |
| SCHEMBL20540428 | 0.75 | ALDH1A1 (0.50) | MEN1KMT2ASMN1; SMN2HTTNPC1 | |
| SCHEMBL4910016 | 0.75 | KMT2A (0.63) | MEN1KMT2ASMN1; SMN2HTTNPC1 | |
| SCHEMBL14710744 | 0.74 | SMN1; SMN2 (0.53) | MEN1KMT2ASMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11980609-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4337641-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-3853232-B1 | OXABICYCLO ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20220411405-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2022-12-29 | — | — | US | disclosed |
| US-20210317131-A1 | OXABICYCLO ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2021-10-14 | — | — | US | disclosed |
| EP-3853232-A1 | OXABICYCLO ACIDS AS LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2021-07-28 | — | — | EP | disclosed |
| WO-2020060914-A1 | OXABICYCLO ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-26 | — | — | WO | disclosed |
| US-7851473-B2 | Amide compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20080312226-A1 | Amide Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312226-A1 | Amide Compound | FAAH, FAAH2, CNR2 | MEN1 3363/4885KMT2A 261/4885SMN1; SMN2 2454/4885 |
| US-20210317131-A1 | OXABICYCLO ACIDS AS LPA ANTAGONISTS | LPAR1, LPAR2, LPAR3 | MEN1 3637/4885KMT2A 3689/4885SMN1; SMN2 3487/4885 |
| US-11980609-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | MEN1 4641/4885KMT2A 2043/4885SMN1; SMN2 4824/4885 |
| US-20220411405-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | MEN1 4641/4885KMT2A 2043/4885SMN1; SMN2 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.